QIPP Pharmacist & Prescribing Advisor for BHR CCGs Prescribing Advisor for BHR CCGs, representing Barking & Dagenham (B&D) CCG
|
|
- Barnard Kennedy
- 5 years ago
- Views:
Transcription
1 BHR CCGs AREA PRESCRIBING SUB-COMMITTEES Thursday 17 th September 2015 BOARDROOM A, BECKETTS HOUSE, ILFORD, IG1 2QX PRESENT Dr G Kalkat (GK) Oge Chesa (OC) Belinda Krishek (BK) Mohamed Kanji (MK) Julia Quant (JQ) Sanjay Patel (SP) Imran Khan (IK) Olufunlola Apakama (OA) Saiqa Mughal (SM) Heather Walker (HW) Dr C Okorie (CO) Dr A Tran (AT) Tutu Ogunsanwo (TO) Dr K Kugathas (KK) Dr U Haque (UH) Imran Jan (IJ) Diane Meid (DM) Denise Baker (DB) APOLOGIES Yemi Osho IN ATTENDANCE Dr Khalid Saja Chair, GP, Clinical Director Prescribing Lead, Barking & Dagenham (B&D) Clinical Commissioning Group (CCG) Deputy Chief Pharmacist, Barking & Dagenham, Havering and Redbridge CCGs (BHR CCGs) Chief Pharmacist, BHR CCGs Prescribing Advisor for BHR CCGs, representing Havering CCG Prescribing Advisor for BHR CCGs, representing Redbridge CCG QIPP Pharmacist, BHR CCGs QIPP Pharmacist & Prescribing Advisor for BHR CCGs Prescribing Advisor for BHR CCGs, representing Barking & Dagenham (B&D) CCG Prescribing Advisor for BHR CCGs, representing Redbridge CCG Chief Pharmacist, NELFT GP, Clinical Director Prescribing Lead, Redbridge CCG GP, Clinical Director Prescribing Lead, Havering CCG Formulary Pharmacist, Barking Havering and Redbridge University Hospital Trust (BHRUT) GP, Redbridge Local Medical Committee (LMC) Representative GP, Barking and Havering Local Medical Committee (LMC) Representative Pharmacist, North East London (NEL) Local Pharmaceutical Committee (LPC) Lay member Business Manager, BHR CCG s Interim Head of Nursing, Partnership of East London Cooperative (PELC) Consultant Haematologist, BHRUT 1 P a g e
2 25.1 Welcome / Introduction / Apologies A list of apologies was received as shown on page 1. The Chair thanked the Barking and Havering Local Medical Committee (LMC) for their contribution and support to the committee and was welcomed the new representative who would be attending future meetings. Action and by whom The committee was advised that the lunch provided at the meeting had not been sponsored by a pharmaceutical company and that all future meetings where lunch was required would be accounted to BHR CCGs; pharmaceutical sponsorship would not be requested for any future APC meetings Declarations of potential conflicts of interest None were received Minutes of the previous meeting The minutes of the previous meeting were agreed with an amendment to item 24.5 on page 3. The redacted minutes for the May 2015 were agreed for addition to the BHR CCG websites. - Amend the following action: Page 3, Prescribing guidelines of infant formula for infants with Cow s Milk Protein Allergy (CMPA) Liaise with paediatricians, neonatologists and outreach nurses to review the guideline - Add the agreed redacted minutes to the BHR CCG websites 25.4a Prescribing in alcohol detoxification regimes (item 24.4a in July minutes) We were advised that a service with prescribing responsibility had been commissioned from the Westminster Drug Project (WDP) for the borough of Havering and would commence from the 1 st October A response regarding a service in Barking and Dagenham was still awaited and the chair advised that a Prescribing Lead, LBBD would be contacting the medicines management team to consider the prescribing element as an enhanced service. 25.4b Shared Care Guideline Checklist (item 24.4b in July minutes) There was no update as to the progress in the provision of an e-platform for shared care guidelines at BHRUT. It was therefore agreed that a letter from the Chair on behalf of the committee would be forwarded to BHRUT requesting an update for this item. 25.4c New drug evaluation for DuoResp Spiromax (item 24.4c in July minutes) BHRUT advised that a respiratory lead together with the Respiratory Lead Pharmacist had produced a draft formulary of preferred devices for the management of asthma and a meeting was to be arranged with the Medicines Management team. Once this meeting had taken place and the formulary agreed it would be submitted to the BHRUT Drugs and Therapeutics Committee (DTC) for approval. The urgency for this meeting was noted. - Update to be provided at a future meeting Chair - To forward a letter to BHRUT requesting an update on the progress of the e-platform for shared care guidelines - To liaise with BHRUT and arrange a meeting to agree the draft formulary before submission to the BHRUT DTC for consideration at its next meeting 2 P a g e
3 25.4d Evidence behind the proposed amendments to the Dementia Share Care Guideline (SCG) (NELFT) (item 24.4d in July minutes) A revised draft shared care guideline incorporating the agreed amendments including combination therapy as an option, was not yet available for consideration. An update would be requested from the Associate Medical Director, NELFT, regarding availability of the draft document for the next meeting. 25.4e Formation of an outer NEL Antimicrobial Resistance Strategy Group (AMRSG) (item 24.4e in July minutes) We were provided background to the formation of the outer NEL AMRSG and details of the stakeholders that had attended the inaugural meeting on 27 th July At this meeting discussions had focused on preparing for the forthcoming European Antibiotic Awareness Day on 18 th November together with identifying various works areas which were collated in a draft work-plan for consideration at the next meeting, 1 st October f Prescribing guidelines of infant formula for infants with Cow s Milk Protein Allergy (CMPA)(item 24.5 in July minutes) We were advised that the NELFT dietitians were in the process of updating the guidelines with the comments received from the previous APC meeting, together with additional comments received from the paediatricians and the neo-natal nurses in BHRUT. Assurance was provided that the revised document would address the prescribing queries and issues being experienced by GP practices. 25.4g Labelling of Insulin pens by community pharmacies (BHRUT)(item 24.6 in July minutes) We were advised by the LPC representative that there had not been an opportunity to review the paper previously circulated regarding this item and was therefore the LPC representative unable to provide any comments on behalf of the North East London Local Pharmaceutical Committee (LPC). It was agreed that this item would be deferred to the APC meeting in November. NELFT - Produce the revised draft SCG for consideration at the November APC meeting - To provide an update at the next APC meeting NELFT - To produce the revised CMPA guidance for consideration and approval at the November APC meeting LPC - To ensure comments of LPC members are available to support discussion at the November APC meeting Agenda item for the November APC meeting GP access to carbon-13 urea breath test in re-testing for helicobacter pylori infection (BHR CCGs) We were informed that currently a urea breath test service was not available for GP practices to access at either BHRUT or Barts Health Trust. Subsequently, the medicines management team had prepared a report to outline two possible options to ensure that an agreed method was in place to access carbon-13 urea breath tests in re-testing for H.pylori eradication across the three boroughs; currently insufficient evidence was available to recommend the stool antigen test for eradication. NELCSU - To provide cost analysis of the following: Cost of stool antigen testing vs urea breath test Explore the option of an enhanced service proposal Explore the use of a specialist department to access the service - To establish the number of stool antigen positives identified for the year from Health Analytics 3 P a g e
4 Both the following options were discussed and the conclusions reached: Option 1: Pursue a commissioned service with local acute providers; the cost of provision will require negotiation - this service was not commissioned in the current contract but could be negotiated with the respective Acute Trust for the future Option2: Advise practices that carbon-13 urea breath test kits are prescribable on FP10, will bypass the costs incurred from laboratory interpretation of the findings - concerns were raised regarding the time and resources that would be necessary to conduct the tests within GP practices, once the patients had obtained the breath test kit and returned for a further appointment. One member described his experience of using the breath test kit in practice. It was agreed that costings should be established relating to both the stool antigen and the urea breath tests and the possibility of an enhanced service proposal, or access to specialist service should also be considered. The NEL Commissioning Support Unit would be requested to provide full details of the above for the November APC meeting. It was also agreed that would request from the Health Analytics team data identifying the number of positive stool antigen tests across BHR for the year, which would give an idea of potential numbers requiring re-testing. Further discussion required, agenda item for the November APC meeting Safe and legal driving for people on medicines with health problems handy fact sheet (BHR CCGs) A revised version of the original document considered at a previous APC meeting had been circulated as consent had since been received from the original authors for amendments to be made. It was noted that the revised version had also been circulated to the patient engagement forum and it was confirmed that LMC members had also considered the suggested amendments and required the final copy for the LMC newsletter. - The following amendments were requested to the fact sheet: Remove the question mark from the statement Do I need to drive Remove from the last paragraph of the section What are the new laws that came into force on 2 nd March 2015? or our website for more information Remove the from the first sentence in the section Medical rules for all drivers This document was agreed subject to amendments Novel Oral Anticoagulants (NOACs) in Primary Care (BHRUT) a) Follow up and Transfer of Care Letter anticoagulant therapy for AF b) Notification Letter Initiation of Warfarin therapy for AF c) Notification Letter Initiation of anticoagulant therapy for AF A Consultant Haematologist from BHRUT was welcomed to the meeting having prepared the above three letters in response to the request from the previous APC meeting. Haematologist - Add copy to patient on each letter to ensure that they are received - Add all three letters once finalised to CCGs websites The circulated letters were considered and with the added requirement of patients also receiving a copy of the letter addressed to the GP, all three letters received approval. 4 P a g e
5 All three letters approved subject to amendment. Rivaroxaban Shared Care Guideline & Apixaban Shared Care Guideline (SCG) - both documents had been circulated prior to the meeting but not in time for inclusion on the agenda. Both documents were discussed and it became apparent that they did not truly reflect a shared care treatment guideline but were in fact providing information for transfer of care to the GP. Several amendments were requested including a change to the layout so that the look of the document differed from the SCG template thus avoiding any possible confusion amongst clinicians. It was suggested that the relevant areas to be included in the transfer of care documents be identified so that he was able to produce documents that would be suitable for approval at the next APC meeting. Discussions also included responsibility and the legalities of the documents and the necessary training and recall mechanisms required to support transfer to primary care. The consultant haematologist advised that he would consider all these elements within the new documents. BHRUT - To prepare Transfer of Care documents in respect for Dabigatran, Rivaroxaban and Apixaban in the management of Atrial Fibrillation (AF). They should include the following: Normal dose and administration Monitoring standards Key adverse effects and actions Pregnancy and breast feeding Important considerations including dental procedures Contact numbers It was highlighted that several anti-coagulation studies were currently taking place to monitor the impact of NOAC use to date. We were advised of the Orange Registry a national three year study underway collecting major haemorrhage data identifying for example, those associated with aspirin, falls, patients with dementia and warfarin. Data so far had shown that for both GI and cerebral bleeds findings reflected those of the trials. However, mortality was equivalent between both NOACs and warfarin although the majority of bleeds had been in patients receiving warfarin than rivaroxaban. It was felt that the higher mortality for both may be because most sites were neurological centres so skewing the data. Once more District General Hospital (DGH) data was obtained it may taper down. A PHD fellow working at the London Hospital was due to start an adherence study; the study protocol was still unknown but BHRUT had agreed to participate. Transfer of care documents to be submitted for consideration at the next APC meeting Vaccine Fridge Temperature Out of Range Guidance (BHR CCGs) We were advised that due to a number of recent enquiries regarding fridge temperature incidents, guidance has been produced to support practices with decision making following a deviation in temperature range from the recommended +2 to 8 C range. The draft guidance provided contact details for the various vaccine manufacturers together with algorithms for managing cold chain breaches where vaccines had and had not been administered to patients. It was to be noted that the algorithms were taken from a document produced by the Health Protection Agency (HPA) in 2012 and did not therefore display organisational changes that had since taken place. A note to this effect was to be added to the front page of the guidance. - Add the following information to page 1 of the guidance: Bullet point 1, the following statement to be added Please note Some of the acronyms may be out of date however the flowchart is current. Add bullet point 6 Practice staff should consider keeping an internal record of such incidents, actions taken and any significant lessons learnt if applicable which would be useful for CQC inspections. Reference CQC requirements if found - Provide details of the guidance at future GP and Practice Nurse prescribing forums 5 P a g e
6 A discussion commenced regarding the use of data loggers and whether this was now a requirement for GP practices to implement as part of CQC inspections. However, it was established that whilst a data logger would assist practices with fridge temperature incidents, the CQC website would be searched for evidence of this requirement as to cite in the guidance where necessary. This document was approved subject to amendments Guidelines for the diagnosis and management of Vitamin D deficiency in adult patients (BHRUT/BHR CCGs) The above guidance had been reviewed and we were informed about minor amendments which had been made to the document following NICE s public health update on vitamin D and increasing supplement use. The management strategy for treatments had remained the same as previously agreed. - The following amendments were requested to page 3: Vitamin D in pregnancy and breast feeding women, paragraph 4 to be reworded Amend NELC to NELFT in the box referring to Vitamin D and Children There was discussion regarding the advice for women during the period of pregnancy and lactation and a further amendment was requested regarding the wording of paragraph four of this section. It was confirmed that the guidance referred only to formulary treatments, however when next reviewed would incorporate supplementation options. The document was agreed subject to amendments for two years /15 Medicines Management End of Year Report (BHR CCGs) We were presented the end of year report for the Medicines Management team 2014/15 and identified certain areas for attention. It was acknowledged that the comprehensive report related to the medicines management work streams for 2014/15 across all three BHR CCGs. The document once amended would be submitted for noting at each CCG s next board meeting. - Amend the report with the following: Page 6, Redbridge CCG, point 2 amend underspend to overspend - Submit the full report to each CCG s board meeting for noting Approved subject to amendment North East London(NEL)/North Central London(NCL) Ophthalmology Pathways We were advised that the following two ophthalmology pathways had been produced through joint working between Moorfields Eye Hospital, eye units across NEL & NCL and respective commissioners, and were now required to be agreed for use locally. Branch Retinal Vein Occlusion (BRVO) Pathway Central Retinal Vein Occlusion (CRVO) Pathway 6 P a g e
7 Both documents were approved for local use Modified Release Quetiapine and Galantamine Preparations (BHR CCGs) We were informed that due to financial pressures, the committee should consider switching prescribing of quetiapine XL and galatamine XL to cost effective brand options. Details of possible savings had been explored and provided in the paper circulated. It was to be noted that the change for both quetiapine and galantamine preparations would only be for patients receiving XL formulations. The paper identified the following brands as the most cost effective for primary care: Galentex XL (Creo Pharma Ltd) and Luventa XL (Fontus Health Ltd) for galatatmine XL Zaluron XL (Fontus Health Ltd) for quetiapine XL NELFT - to forward their paperwork (PIL and letter) regarding XL to immediate release (IR) switch - Produce letter to support the switch, including rationale and reference areas to minimise patient concerns - Set clear criteria for switching of patients - Add details to the CCGs websites - to explore the quetiapine XL to IR switch We were advised that since this document had been prepared prices had changed and Zaluron ZL tablets and Sondate XL tablets (TEVA Ltd) were now priced the same for quietiapine XL and should therefore also be considered. Fontus Health Ltd and TEVA Ltd had provided sufficient price guarantees and as at least two companies had been chosen there was some reassurance if any one product was temporarily unavailable. Concerns were raised regarding bio equivalence and interchangeability of the drugs. It was acknowledged that whilst this information was not available to support this work initiative discussions had been had with NELFT who had not identified any concerns regarding this switch. It was confirmed that NELFT currently prescribed generically for these drugs and therefore this work area would not affect any prescribing within the community services. A letter would be produced for general practice which would include rationale and address the concerns raised. We were provided with details of other areas where switches to branded generic XL formulations had occurred -Birmingham, States of Guernsey, NHS Anglia & Norfolk. It was noted that for quetiapine, the most savings were in a XL to IR switch and it was agreed to explore further this switch. It was stated that quetiapine XL was non formulary at NELFT and that a paper had been presented previously for this switch. Approved to address the XL prescribing for both quetiapine and galantamine preparations using the most cost effective brands End of Year Report: Cost avoidance from use of Outpatient Parenteral Antibiotic Therapy (OPAT) in conjunction with the Royal National Orthopaedic Hospital (RNOH) - To discuss a possible change to the process in consenting of patients for the service 7 P a g e
8 (BHR CCGs) We were provided background to this report explaining the work that had been undertaken during the past two years which had enabled RNOH patients to receive the continuation of IV antibiotics post discharge in the community in their homes; thus avoiding the cost of an inpatient stay. whilst maintaining the monitoring of appropriateness of treatments It was reported that patient discharge was subject to the approval of the Chief Pharmacist which implied that if she were to be on annual leave patients would remain in hospital. All were in agreement that the current commissioning arrangement for utilisation of the post discharge arrangement with RNOH was to continue. However, it was agreed that the medicines management team should liaise with the Deputy Director Chief Pharmacist, North East London Commissioning Support Unit (NELCSU) regarding the current need to refer each individual patient for the service which was extremely time consuming for the medicines management team; however verification and monitoring arrangements would still be required. Report was noted Adrenaline Auto-injectors a review of clinical and quality considerations We were informed that Barts Health NHS Trust were considering a switch from Epipen to Emerade auto injectors for the following: i. New diagnosis:initiate Emerade ii. Patients on Epipen presenting with anaphylaxis: Switch to Emerade (as supply of Epipen with likely have been used) iii. Patients on Epipen being reviewed in clinic / not presenting with anayphylaxis: remain on Epipen until their supply is expired. Then advise GP to prescribe Emerade for future supplies BHRUT - To ensure Emerade is considered at a future DTC meeting NELFT - To consider Emerade for use by community services - to feedback APC response to Barts Health NHS Trust It was also stated that a concern was raised as to whether patients would know how to use the new device, however it was explained that the auto-injector had a similar mechanism. It was also acknowledged that the Emerade device had a longer needle to ensure IM administration as outlined as a potential benefit within the document, MHRA Adrenaline Auto-injectors: A Review of Clinical and Quality Considerations (June 2014). We were advised that BHRUT were unaware of the Emerade device and would therefore refer the product details to the BHRUT Drugs & Therapeutics Committee (DTC) for consideration and would also liaise with the Resuscitation Committee for feedback. It was confirmed that NELFT would also consider the new device for use within community services. Strategy for a switch from Epipen to Emerade was approved for Barts Health NHS Trust. 8 P a g e
9 25.15 Rivaroxaban proposal for the preventions of stroke and embolism in adults with non valvular atrial fibrillation in the NELFT (BHR CCGs Health Economy) The above proposal had been presented which outlined three possible options with regard to the prescribing of rivaroxaban within NELFT; due to a delay in patients being offered rivaroxaban once warfarin had been established as not appropriate, NELFT clinicians were seeking approval to initiate rivaroxaban for appropriate patients. It was highlighted that NELFT clinicians were not commissioned or had the funding available to prescribe rivaroxaban however this proposal could be considered as part of the commissioning intentions for 2016/17. After discussion, Option 3 was agreed as the preferred option maintaining the current practice of referral to the anti-coagulation service within BHRUT for initiation of NOACs. Option 3 agreed Herpes Zoster Vaccine GP Patient Specific Direction (NELFT) The above document had been reviewed and the amendments had been highlighted in red on the circulated version. It was confirmed that the Patient Specific Direction (PSD) would be used for housebound patients and patients who were already part of the district nurses caseload. It was to be noted that multiple names were not to be added to the PSD as each patient record would require a copy of the document filed. Approved for use Pneumococcal Polysaccharide Vaccine GP Patient Specific Direction (NELFT) The above document had been reviewed and the amendment had been highlighted in red on the circulated version. It was confirmed that the Patient Specific Direction (PSD) would be used for housebound patients and those who were already part of the district nurses caseload. It was to be noted that multiple names were not to be added to the PSD as each patient record would require a copy of the document filed. Approved for use Summaries of BHR CCGs Prescribing Incentive Scheme 2014/15 & 2015/16 The above summaries had been circulated for information purposes and were noted Any other business None For information a. Barts Health NHS Trust & Local GPs Joint Prescribing Group minutes for February & March P a g e
10 b. BHRuT DTC minutes for February & March 2015 c. BHR CCGs APC final minutes for May 2015 d. Important new evidence relating to prescribing and medicines optimisation June Documents approved subject to amendments since last BHR CCGs APC meeting: Shared Care for Vitamin D prescribing in children Letter regarding Repeat Dispensing PELC PGDs (six) Date of next meeting: Thursday, 5 th November at 12.30, Boardroom A, Becketts House, Ilford 10 P a g e
Prescribing Advisor for BHR CCGs, representing Barking & Dagenham (B&D) CCG Prescribing Advisor for BHR CCGs, representing Redbridge CCG
BHR CCGs AREA PRESCRIBING SUB-COMMITTEES Thursday 5 th November 2015 BOARDROOM A, BECKETTS HOUSE, ILFORD, IG1 2QX PRESENT Dr G Kalkat (GK) Oge Chesa (OC) Belinda Krishek (BK) Dr C Okorie (CO) Dr K Kugathas
More informationPrescribing Advisor for BHR CCGs, representing Barking & Dagenham (B&D) CCG Prescribing Advisor for BHR CCGs, representing Redbridge CCG
BHR CCGs AREA PRESCRIBING SUB-COMMITTEES Thursday 7 th January 2016 BOARDROOM A, BECKETTS HOUSE, ILFORD, IG1 2QX PRESENT Dr G Kalkat (GK) Oge Chesa (OC) Belinda Krishek (BK) Dr C Okorie (CO) Dr K Kugathas
More informationBHR CCGs AREA PRESCRIBING SUB-COMMITTEES TUESDAY 22 ND APRIL 2014 BOARDROOM A, BECKETTS HOUSE, ILFORD, IG1 2QX
PRESENT Dr M Hamilton-Farrell (MHF) Chairperson for this meeting Dr G Kalkat (GK) Dr C Okorie (CO) Dr R Adur (RA) Oge Chesa (OC) Belinda Krishek (BK) Sanjay Patel (SP) Heather Walker (HW) Dinesh Gupta
More informationBHR CCGs AREA PRESCRIBING SUB-COMMITTEES Thursday 5 th October 2017 Boardroom, 3 rd Floor, Imperial Offices, 2-4 Eastern Road, Romford, RM1 3PJ
BHR CCGs AREA PRESCRIBING SUB-COMMITTEES Thursday 5 th October 2017 Boardroom, 3 rd Floor, Imperial Offices, 2-4 Eastern Road, Romford, RM1 3PJ PRESENT Dr G Kalkat (GK) Oge Chesa (OC) Belinda Krishek (BK)
More informationBHR CCGs AREA PRESCRIBING SUB-COMMITTEES Tuesday 20 th February 2018 Boardroom, Maritime House, Barking, IG11 8HG
BHR CCGs AREA PRESCRIBING SUB-COMMITTEES Tuesday 20 th February 2018 Boardroom, Maritime House, Barking, IG11 8HG PRESENT Dr G Kalkat (GK) Oge Chesa (OC) Belinda Krishek (BK) Dr S Raza (SR) Dr A Tran (AT)
More informationSouth East London Area Prescribing Committee (APC) 9 October at Lower Marsh. Final minutes
South East London Area Prescribing Committee (APC) 9 October at Lower Marsh Final minutes 1. Welcome, Introductions and Apologies received. 2. Conflicts of Interest declarations The Chair requested any
More informationNHS BARNSLEY. Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on Wednesday 13 th February 2013 in the Boardroom at Hillder House.
Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on Wednesday 13 th February 2013 in the Boardroom at Hillder House. PRESENT: Dr M Ghani (Chair) Medical Director Barnsley CCG (Designate) Dr
More informationNorth Central London Medicines Optimisation Network. Terms of Reference. North Central London Medicines Optimisation Network 1 of 8
North Central London Medicines Optimisation Network Medicines Optimisation Committee Terms of Reference North Central London Medicines Optimisation Network 1 of 8 Document control Date Version Amendments
More informationPrescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services
Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Document Purpose Version 2.2 To detail the specific contractual issues associated with prescribing
More informationSouth East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide
South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning
More informationANTI-COAGULATION MONITORING
ANTI-COAGULATION MONITORING 2016-17 a) Purpose of Agreement This Agreement outlines the service to be provided by the Provider, called an Anti-coagulation monitoring service. b) Duration of Agreement This
More informationTo contact us please
Issue 13, June 2015 Newsletter for Care Home staff, General Practitioners and Community Pharmacists The Caring for Care Homes team produced The Medicines Management Checklist in 2010 to provide care homes
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationWolverhampton CCG Commissioning Intentions
Wolverhampton CCG Commissioning Intentions 2015-16 * Areas of particular focus and priority CI Ref Contract Provider Brief CI001 CI002 CI003 Child Protection Information Sharing Implement the new Child
More informationLinda Cutter / Dr Charles Heatley. GP Practices and Community Pharmacies
Schedule 2 Part A Service Specification Service Specification No. 04 Service Anti-coagulation Monitoring Levels 3, 4 & 5 Commissioner Lead Provider Lead Linda Cutter / Dr Charles Heatley GP Practices and
More informationWest Midlands Strategic Clinical Network & Senate Improving the detection and management of Atrial Fibrillation in Primary Care
West Midlands Strategic Clinical Network & Senate Improving the detection and management of Atrial Fibrillation in Primary Care Good Practice Guide Improving the detection and management of Atrial Fibrillation
More informationSouth East London Area Prescribing Committee (APC) 13 October 2016 at Lower Marsh Approved minutes 1. Welcome, and Introductions
South East London Area Prescribing Committee (APC) 13 October 2016 at Lower Marsh Approved minutes 1. Welcome, and Introductions 2. Conflicts of Interest declarations The Chair requested any interests,
More informationMinutes of the Lambeth and Southwark Joint Prescribing Committee (JPC) meeting pm, Wednesday 15 May 2013 Room GO2-A, 160 Tooley Street
Minutes of the Lambeth and Southwark Joint Prescribing Committee (JPC) meeting 2. 00 pm, Wednesday 15 May 2013 Room GO2-A, 160 Tooley Street Present: Dr Catherine Otty (CO) Dr Alan Campion Dr Sian Howell
More informationWOLVERHAMPTON CCG. Governing Body Meeting 8 April 2014
WOLVERHAMPTON CCG Governing Body Meeting ` Agenda item:12 TITLE OF REPORT: REPORT PRESENTED BY: Commissioning Committee Summary Dr Kamran Ahmed Title of Report: Update from the Commissioning Committee
More informationDelivering the QIPP programme: making existing services improve patient outcomes
Delivering the QIPP programme: making existing services improve patient outcomes Produced by Glyn Davies MP, Chair All-Party Parliamentary Group on AF in association with the Atrial Fibrillation Association
More informationInformation shared between healthcare providers when a patient moves between sectors is often incomplete and not shared in timely enough fashion.
THE DISCHARGE MEDICINES REVIEW SERVICE Introduction During a stay in hospital a patient s medicines may be changed. Studies show that many patients may experience an error or problem with their medicines
More informationIs Our South East London Area Prescribing Committee Working To Best Practice, Or Could We Be Even Better?
Is Our South East London Area Prescribing Committee Working To Best Practice, Or Could We Be Even Better? Vanessa Burgess, Assistant Director, Medicines & LTCs, NHS Lambeth Clinical Commissioning Group;
More informationPOWYS TEACHING HEALTH BOARD PRIMARY CARE PRESCRIBING AND THERAPEUTICS COMMITTEE
POWYS TEACHING HEALTH BOARD Meeting 04/12/12 Present: PRIMARY CARE PRESCRIBING AND THERAPEUTICS COMMITTEE Minutes of the meeting held on Thursday, 06 September 2012 at 09.30am in Training Room 1, Bronllys
More informationPrescribing Quality Review Scheme (PQRS) 2016/17
Introduction: The Prescribing Quality Review Scheme (PQRS) has been designed to reflect the four key principles of medicines optimisation: Understanding and improving patient experience. Evidence based
More informationAnticoagulation Manager Training Day Plan
Anticoagulation Manager Training Day Plan Versioning Author: Debbie Cuthbert/Emma Stubbs Reviewer(s): Debbie Cuthbert, Jim Holden Date Version Contents 22/10/2014 01 Initial draft day plan. 31/10/2014
More informationAll Wales Multidisciplinary Medicines Reconciliation Policy
All Wales Multidisciplinary Medicines Reconciliation Policy June 2017 This document has been prepared by the Quality and Patient Safety Delivery Group of the All Wales Chief Pharmacists Group, with support
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationCamden Clinical Commissioning Group Reporting Mechanism/Frequency Remotely/Quarterly
Universal Offer Service Anticoagulation - Warfarin Clinical Lead Dr Kevan Ritchie Commissioner Camden Clinical Commissioning Group Reporting Mechanism/Frequency Remotely/Quarterly Payment Frequency Quarterly
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationMedicines Reconciliation: Standard Operating Procedure
Clinical Medicines Reconciliation: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationMs Lyndsey Hands, Graduate Trainee (observer) Mrs Sandra MacDonald (minutes) ACTION
CONFIRMED MINUTES OF THE MEETING OF THE FIFE DRUGS AND THERAPEUTICS COMMITTEE HELD AT 12.30PM ON WEDNESDAY 16 AUGUST 2017 IN MEETING ROOM 2, WARD 6, VICTORIA HOSPITAL, KIRKCALDY. Present: Mrs Evelyn McPhail
More informationBest Practice Guidelines - BPG 9 Managing Medicines in Care Homes
Best Practice Guidelines - BPG 9 Managing Medicines in Care Homes Medicines in Care Homes 1 DOCUMENT STATUS: Approved DATE ISSUED: 10 th November 2015 DATE TO BE REVIEWED: 10 th November 2017 AMENDMENT
More informationPlease note this scheme is only for re-tests. Stool samples should be used for initial diagnosis tests.
Specification for Local Improvement Scheme Carbon 13 Helicobacter Urea Breath Testing Introduction The local improvement scheme has been designed by NHS Liverpool Clinical Commissioning Group to facilitate
More informationInitiation of Warfarin for patients not registered with Provider Practice
Initiation of Warfarin for patients not registered with Provider Practice 2017-18 1. Purpose of Agreement This Agreement outlines the service to be provided by the Provider, called Initiation of Warfarin
More informationNHS community pharmacy advanced services Briefing for GP practices
NHS community pharmacy advanced services Briefing for GP practices August 2013 This document has been developed jointly by NHS Employers, the Pharmaceutical Services Negotiating Committee (PSNC) and the
More informationNon-Medical Prescribing Passport. Reflective Log And Information
Non-Medical Prescribing Passport Reflective Log And Information Non-Medical Prescribing Continued Profession Development Log NMPs must refer to their regulatory bodies requirements for maintaining and
More informationCommissioning Policy
Commissioning Policy Consultant to Consultant Referrals Version 6.0 December 2017 Name of Responsible Board / Committee for Ratification: North Staffordshire CCG Stoke on Trent CCG Date Issued: November
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationSetting up the NOAC Service & Taking it to Primary Care
Setting up the NOAC Service & Taking it to Primary Care Satinder Bhandal Consultant Anticoagulation Pharmacist November 2015 Buckinghamshire Health Care NHS Trust Quiz 1. What is the most serious side
More informationAnaphylactic Reaction Emergency Treatment Reference Number:
This is an official Northern Trust policy and should not be edited in any way Anaphylactic Reaction Emergency Treatment Reference Number: NHSCT/12/551 Target audience: Nursing Staff Groups included are:
More informationMEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY
MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt
More informationNon Medical Prescribing Policy
Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:
More informationBristol CCG North Somerset CGG South Gloucestershire CCG. Draft Commissioning Intentions for 2017/2018 and 2018/2019
Bristol CCG North Somerset CGG South Gloucestershire CCG Draft Commissioning Intentions for 2017/2018 and 2018/2019 Programme Area Key intention Primary and community care Sustainable primary care Implement
More informationSection Title. Prescribing competency framework Catherine Picton, Lead author
Prescribing competency framework Catherine Picton, Lead author What is in this presentation Context Uses of the competency framework Scope of the updated prescribing competency framework Introduction to
More informationNHS England London Southside 4th Floor 105 Victoria Street London SW1E 6QT. 24 th July Dear Daniel, Fiona and Louise. Re: CCG Annual Assurance
NHS England London Southside 4th Floor 105 Victoria Street London SW1E 6QT 24 th July 2014 Dear Daniel, Fiona and Louise Re: CCG Annual Assurance Many thanks for meeting with us on 6 th June 2014 to discuss
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes 1.1 Short title Medicines
More informationCroydon Clinical Commissioning Group Clinical Leadership Meeting Minutes
Attachment 16 Appendix 1 Date: 13 July 2012 Time: 13 30 15 30 Location: Room 11.4, Leon House Present: Dev Malhotra, GP Board Member Bobby Abbot, GP Dipti Gandhi, Clinical Leader Brian Okumu, GP Clinical
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationReducing Medication Errors: National Update
Reducing Medication Errors: National Update Ahmed Ameer Medication Safety Officer Ahmed.Ameer@NHS.net Safer Medication Practice & Medical Devices Team 27 th January 2015 Agenda 1. Development of the National
More informationCLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)
CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration
More informationSouth Staffordshire and Shropshire Healthcare NHS Foundation Trust
South Staffordshire and Shropshire Healthcare NHS Foundation Trust Document Version Control Document Type and Title: Authorised Document Folder: Policy for Medicines Reconciliation on Admission and on
More informationApologies for absence were noted from Ms Claire Dobson, Dr I Gourley, Dr J Kennedy, Professor S McLean, Mr I Mohammed.
CONFIRMED MINUTES OF THE MEETING OF THE FIFE DRUGS AND THERAPEUTICS COMMITTEE HELD AT 12.30PM ON WEDNESDAY 4 OCTOBER 2017 IN MEETING ROOM 2, WARD 6, VICTORIA HOSPITAL, KIRKCALDY. Present: Dr Frances Elliot
More informationCCG authorisation: the role of medicines management
May 2012 The NHS medicines bill for 2010 was 12.9 billion, of which secondary care costs accounted for 32%. Prescribing inflation in 2010 ran at 4.8% and it is estimated that around 14% of total CCG budgets
More informationUKMi and Medicines Optimisation in England A Consultation
UKMi and Medicines Optimisation in England A Consultation Executive Summary Medicines optimisation is an approach that seeks to maximise the beneficial clinical outcomes for patients from medicines with
More informationMedicines Management Guidance
Medicines Management Guidance Status Final Version 1.0 Author Jon Boyd Version date 05/12/2016 Agreed by the following North West London CCGs: Central London West London Hammersmith and Fulham Hounslow
More informationDANNOAC-AF synopsis. [Version 7.9v: 5th of April 2017]
DANNOAC-AF synopsis. [Version 7.9v: 5th of April 2017] A quality of care assessment comparing safety and efficacy of edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in patients
More informationRegional Medicines Optimisation Committees
Regional Medicines Optimisation Committees Operating Model First Edition, April 2017 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans.
More informationProcess and methods Published: 23 January 2017 nice.org.uk/process/pmg31
Evidence summaries: process guide Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationNPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing
NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix
More informationNEL Sustainability and Transformation Plan (STP) Communications and engagement plan (phase 2) Contents
NEL Sustainability and Transformation Plan (STP) Communications and engagement plan (phase 2) Contents 1. Aims... 2 1.1 Purpose... 2 1.2 Out of scope... 2 2. Background... 2 3. NEL STP main objectives...
More informationSupporting self-administration of medication in the care home setting
B143. November 2016 2.0 Community Interest Company Supporting self-administration of medication in the care home setting Care home residents should have the opportunity to make informed decisions about
More informationWORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0
WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0 1 Standard Operating Procedure St Helens CCG Working with The Pharmaceutical Industry Policy Version 1.0 Implementation Date May 2017 Review
More information3. Minutes, action log and attendance list of Last Meeting and Matters Arising. The minutes of the March meeting were accepted as accurate.
South East London Area Prescribing Committee (APC) 23 June 2016 at Lower Marsh Approved minutes 1. Welcome, and Introductions 2. Conflicts of Interest declarations The Chair requested any interests, either
More informationOPAT & Paediatric OPAT Standards and Practical Implications for the Hospital and Community. Dr Sanjay Patel & Dr Ann Chapman
OPAT & Paediatric OPAT Standards and Practical Implications for the Hospital and Community Dr Sanjay Patel & Dr Ann Chapman UK OPAT Good Practice Recommendations - Practical considerations and challenges
More informationWestminster Partnership Board for Health and Care. 17 January pm pm Room 5.3 at 15 Marylebone Road
Westminster Partnership Board for Health and Care 17 January 2018 4.30pm - 6.00pm Room 5.3 at 15 Marylebone Road Agenda Item # Item and discussion points Lead Papers Timing 1 Preliminary business Welcome
More informationAny Qualified Provider: your questions answered
Any Qualified Provider: your questions answered September 8, 2011 These answers cover a range of questions about the detail of Any Qualified Provider on integrated care, competition and procurement, liability
More informationSwitch protocol: Brands to generic equivalent
Switch protocol: Brands to generic equivalent Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for
More informationPGDs are permitted for use only by registered health professionals (see enclosed link for full list
NHS England North - Yorkshire and the Humber Region Protocol for the Development, Authorisation and Use of Patient Group Directions for the National Immunisation Programmes 1. Introduction The preferred
More informationDefining the Boundaries between NHS and Private Healthcare. MECCG Policy Reference: MECCG142
Defining the Boundaries between NHS and Private Healthcare MECCG Policy Reference: MECCG142 Target Audience Brief Description (max 50 words) Action Required Equality Impact Assessment Providers of private
More informationAlert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March Action for the NHS and the independent sector
Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes
More informationReview of Local Enhanced Services
Review of Local Enhanced Services 1. Background and context 1.1 CCGs are required to prepare for the phasing out of LESs by April 2014 by reviewing the existing LES portfolio and developing commissioning
More informationReconciliation of Medicines on Admission to Hospital
Reconciliation of Medicines on Admission to Hospital Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For
More informationPromoting Effective Immunisation Practice Guide for Students, Mentors and Their Employers Updated Click Here
Promoting Effective Immunisation Practice Guide for Students, Mentors and Their Employers Updated 2014 Click Here Promoting Effective Immunisation Practice Published Summer 2014 NHS Education for Scotland
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications 1 Introduction Anticoagulants are medicines which slow down the blood clotting process and are used to support the prevention of clot development. They
More informationBabylon Healthcare Services
Babylon Healthcare Services Limited Babylon Healthcare Services Ltd. Inspection report 60 Sloane Avenue London SW3 3DD Tel: 0207 1000762 Website: www.babylonhealth.com Date of inspection visit: 4 July
More informationMedicines Use and Safety Annual Report The first stop for professional medicines advice. MUS Annual Report vs2 CL 1
Medicines Use and Safety Annual Report -17 The first stop for professional medicines advice www.sps.nhs.uk MUS Annual Report -17 vs2 CL 1 The Medicines Use and Safety (MUS) Team are part of the NHS Specialist
More informationCentral Alerting System (CAS) Policy
Document Title Reference Number Lead Officer Author(s) (name and designation) Ratified By Central Alerting System (CAS) Policy NTW(O)17 Gary O Hare Executive Director of Nursing and Operations Tony Gray
More informationDocument ref. no: Trust Policy and Procedure PP(16)238 MANAGEMENT OF ADULT PATIENTS TREATED WITH ORAL ANTICOAGULANTS. Approved
Document ref. no: Trust Policy and Procedure PP(16)238 MANAGEMENT OF ADULT PATIENTS TREATED WITH ORAL ANTICOAGULANTS For use in: For use by: For use for: Document owner: Status: West Suffolk NHS Foundation
More informationDIAGNOSTIC CLINICAL TESTS AND SCREENING PROCEDURES MANAGEMENT POLICY
DIAGNOSTIC CLINICAL TESTS AND SCREENING PROCEDURES MANAGEMENT POLICY (To be read in conjunction with Diagnostic Imaging Requesting and Interpreting Radiographs by Non Medical Practitioners Policy, Consent
More informationThoracic surgery medicines
Addressograph Name: Date of birth: Hosp No: NHS No: Thoracic surgery medicines A patient s guide Medicine name Date last dose to be taken 1 Introduction This booklet is for patients waiting to have thoracic
More informationMedicines Management Strategy
Medicines Management Strategy 2012 2014 Directorate responsible for the strategy: Medical and Governance Directorate Staff group to whom it applies: All clinical staff and Trust managers Issue date: 30/6/12
More informationSOUTH EAST CHCP PROFESSIONAL EXECUTIVE GROUP MINUTE OF MEETING HELD ON 21 ST JANUARY 2010 AT SAMARITAN HOUSE
South East Community Health & Care Partnership (SE CHCP) 29 March 2010 Author Kevin Fellows/Sheena Morrison Paper No. 10/17 SOUTH EAST CHCP PROFESSIONAL EXECUTIVE GROUP MINUTE OF MEETING HELD ON 21 ST
More informationCommunity Pharmacy Multi-compartment Compliance Aids Audit
Community Pharmacy Multi-compartment Compliance Aids Audit Introduction To comply with the NHS contractual requirements associated with the Clinical Governance Essential Service, pharmacy contractors must
More informationImproving compliance with oral methotrexate guidelines. Action for the NHS
Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication
More informationSetting up and running a community IV therapy clinic
Setting up and running a community IV therapy clinic Moving care to the community has been a UK-wide health and social care priority for more than a decade (Royal College of Nursing [RCN], 2013). With
More informationHospital Pharmacy Transformation Plan
Hospital Pharmacy Transformation Plan Introduction In June 2014, Lord Carter of Coles was appointed to the position of Chair of a new NHS Procurement & Efficiency Board to direct the NHS Procurement &
More informationNewham Borough Summary report
Newham Borough Summary report March 2013 Prepared on 18/03/13 by Commissioning Support team Finance and Activity Millions Apr-11 Jun-11 Aug-11 Oct-11 Dec-11 Newham Headlines March 2013 Feb-12 Apr-12 Jun-12
More informationPromoting Effective Immunisation Practice Guide for Students, Mentors and Their Employers Updated Click Here
Promoting Effective Immunisation Practice Guide for Students, Mentors and Their Employers Updated 2011 Click Here Promoting Effective Immunisation Practice Published Summer 2011 NHS Education for Scotland
More informationMINUTES OF THE MEDICINES MANAGEMENT GROUP MEETING
MINUTES OF THE MEDICINES MANAGEMENT GROUP MEETING Date & Time of Meeting: Venue: Wednesday 8 th February 2012 @ 1.30pm Boardroom, Glangwili Hospital, Carmarthen Present: In Attendance: Dr. Carol Llewellyn-Jones,
More informationVenue: Salford St James House Present: Name Designation Organisation CCG members
GREATER MANCHESTER MEDICINES MANAGEMENT GROUP Minutes Date: Thursday 16 th February 2017 Time: 1pm 3pm Venue: Salford St James House Present: Name Designation Organisation CCG members Dr Helen Burgess
More informationEnsuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING
Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Contents Page 1.0 Purpose 2 2.0 Definition of medication error
More informationJOB DESCRIPTION. Pharmacy Technician
JOB DESCRIPTION Pharmacy Technician Issued by AT Medics Primary Care Pharmacy Technician Job Description Job Title: Reporting to: Location: Salary: Job status: Contract: Notice Period: Primary care pharmacy
More informationSouth Canterbury District Health Board
South Canterbury District Health Board - Timaru Hospital Introduction This report records the results of a Surveillance Audit of a provider of hospital services against the Health and Disability Services
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th MARCH 2017 AT 12.30pm IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationCoastal West Sussex Interface Prescribing Policy
Coastal West Sussex Interface Prescribing Policy Agreement between Commissioners: Coastal West Sussex CCG And Providers: Western Sussex NHS Foundation Trust (WSfT) Sussex Community NHS Trust (SCT) Sussex
More informationNewham Borough Summary report
Newham Borough Summary report April 2013 Prepared on 17/04/13 by Commissioning Support team Apr-11 Jun-11 Aug-11 Oct-11 Dec-11 Feb-12 Apr-12 Jun-12 Aug-12 Oct-12 Dec-12 Feb-13 GREE N Finance and Activity
More informationQuality Standards for Enhanced Primary Care Services. Version 1.2
Quality Standards for Enhanced Primary Care Services Version 1.2 September 2014 8831 September 2014 West Midlands Quality Review Service These Quality Standards may be reproduced and used freely by NHS
More information